85 related articles for article (PubMed ID: 34417240)
1. Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML.
Alkassis S; Rizwan A; Daoud L; Chi J
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417240
[TBL] [Abstract][Full Text] [Related]
2. Sweet syndrome induced by FLT3 inhibitors: case report and literature review.
Yang L; Zhang R; Ma H
Hematology; 2024 Dec; 29(1):2337230. PubMed ID: 38563968
[TBL] [Abstract][Full Text] [Related]
3. Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor.
Paudel A; Dhital R; Areoye G; Basnet S; Tachamo N
J Community Hosp Intern Med Perspect; 2020 Jun; 10(3):275-278. PubMed ID: 32850078
[TBL] [Abstract][Full Text] [Related]
4. Bullous Sweet syndrome as a presentation of chronic myelogenous leukaemia.
Abbas SW; Shah Z; Shaikh MU
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36455980
[TBL] [Abstract][Full Text] [Related]
5. Sweet syndrome following the ChAdOx1-S vaccine.
Baker O; Chen KS; Kaminska I; Rajagopal V
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38216167
[TBL] [Abstract][Full Text] [Related]
6. Erythematous Papules, Plaques, and Nodules in a Patient With Acute Myeloid Leukemia.
Fernández-Galván A; Fraga J; Llamas-Velasco M
Actas Dermosifiliogr; 2024 Feb; ():. PubMed ID: 38369280
[No Abstract] [Full Text] [Related]
7. Safety of FLT3 inhibitors in patients with acute myeloid leukemia.
Cerchione C; Peleteiro Raíndo A; Mosquera Orgueira A; Mosquera Torre A; Bao Pérez L; Marconi G; Isidori A; Pérez Encinas MM; Martinelli G
Expert Rev Hematol; 2021 Sep; 14(9):851-865. PubMed ID: 34424108
[No Abstract] [Full Text] [Related]
8. The Prognostic Value and Function of HOXB5 in Acute Myeloid Leukemia.
Chen M; Qu Y; Yue P; Yan X
Front Genet; 2021; 12():678368. PubMed ID: 34421991
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
Cao Y; Afzal MZ; Shirai K
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
[TBL] [Abstract][Full Text] [Related]
10. The role of tumor necrosis factor receptor superfamily member 4 (TNFRSF4) gene expression in diagnosis and prognosis of acute myeloid leukemia.
Gamaleldin MA; Imbaby SAE
Mol Biol Rep; 2021 Oct; 48(10):6831-6843. PubMed ID: 34453673
[TBL] [Abstract][Full Text] [Related]
11. CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.
Tariq MU; Furqan M; Parveen H; Ullah R; Muddassar M; Saleem RSZ; Bavetsias V; Linardopoulos S; Faisal A
Br J Cancer; 2021 Sep; 125(7):966-974. PubMed ID: 34446858
[TBL] [Abstract][Full Text] [Related]
12. Maturation State-Specific Alternative Splicing in
Wojtuszkiewicz A; van der Werf I; Hutter S; Walter W; Baer C; Kern W; Janssen JJWM; Ossenkoppele GJ; Haferlach C; Cloos J; Haferlach T
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439083
[TBL] [Abstract][Full Text] [Related]
13. Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia.
Brunner AM; Newcomb RA; Chen YB; Crabbe AM
N Engl J Med; 2021 Aug; 385(9):834-843. PubMed ID: 34437787
[No Abstract] [Full Text] [Related]
14. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.
Sun J; Ning S; Feng R; Li J; Wang T; Xing B; Zhu X; Zhao Y; Pei L; Liu H
Anticancer Drugs; 2022 Jan; 33(1):e813-e817. PubMed ID: 34459465
[TBL] [Abstract][Full Text] [Related]
15. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
16. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Pal SK; Frankel PH; Mortazavi A; Milowsky M; Vaishampayan U; Parikh M; Lyou Y; Weng P; Parikh R; Teply B; Dreicer R; Emamekhoo H; Michaelson D; Hoimes C; Zhang T; Srinivas S; Kim WY; Cui Y; Newman E; Lara PN
JAMA Oncol; 2021 Oct; 7(10):1536-1543. PubMed ID: 34436521
[TBL] [Abstract][Full Text] [Related]
17. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM
Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers.
Yao K; Liu H; Yin J; Yuan J; Tao H
J Exp Clin Cancer Res; 2021 Aug; 40(1):263. PubMed ID: 34425876
[TBL] [Abstract][Full Text] [Related]
19. Leukocytoclastic vasculitis due to ruxolitinib treatment: A rare adverse effect.
Tığlıoğlu M; Tığlıoğlu P; Yıldız A; Reis Aras M; Sağlam B; Afacan Öztürk HB; Adabağ A; Albayrak M
J Clin Pharm Ther; 2022 Apr; 47(4):544-547. PubMed ID: 34423448
[TBL] [Abstract][Full Text] [Related]
20. Unique challenges to diagnosing sweet syndrome following induction chemotherapy for relapsed Acute Myeloid Leukemia (AML): A case and brief-review.
Nazaretyan S; Ali A; Yaghmour G; Tong A; Castillo V; Rodrigues S; Ladha A; Woan K; Tam E; Shi SY; Bateshansky D; Chaudhary PM
Respir Med Case Rep; 2023; 46():101922. PubMed ID: 37841284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
